Research Analysts’ Recent Ratings Updates for Elevance Health (ELV)

A number of firms have modified their ratings and price targets on shares of Elevance Health (NYSE: ELV) recently:

• 6/8/2026 – Elevance Health had its price target raised by Mizuho from $435.00 to $465.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – Elevance Health had its price target raised by JPMorgan Chase & Co. from $411.00 to $476.00. They now have an “overweight” rating on the stock.
• 6/4/2026 – Elevance Health had its price target raised by Bank of America Corporation from $435.00 to $460.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Elevance Health had its price target raised by Morgan Stanley from $352.00 to $404.00. They now have an “equal weight” rating on the stock.
• 6/1/2026 – Elevance Health had its price target raised by Truist Financial Corporation from $375.00 to $450.00. They now have a “buy” rating on the stock.
• 5/26/2026 – Elevance Health had its price target raised by Barclays PLC from $408.00 to $480.00. They now have an “overweight” rating on the stock.
• 5/22/2026 – Elevance Health had its price target raised by UBS Group AG from $400.00 to $460.00. They now have a “buy” rating on the stock.
• 5/20/2026 – Elevance Health had its price target raised by Mizuho from $385.00 to $435.00. They now have an “outperform” rating on the stock.
• 5/20/2026 – Elevance Health was upgraded by Deutsche Bank Aktiengesellschaft from “hold” to “buy”. They now have a $498.00 price target on the stock, up from $363.00.
• 5/19/2026 – Elevance Health had its “hold” rating reaffirmed by Evercore Inc.
• 5/18/2026 – Elevance Health was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 4/29/2026 – Elevance Health was upgraded by Citigroup Inc. to “buy”.
• 4/29/2026 – Elevance Health was upgraded by Bank of America Corporation from “neutral” to “buy”. They now have a $435.00 price target on the stock, up from $405.00.
• 4/28/2026 – Elevance Health had its price target raised by JPMorgan Chase & Co. from $397.00 to $411.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Elevance Health was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 4/24/2026 – Elevance Health had its price target raised by Guggenheim from $396.00 to $399.00. They now have a “buy” rating on the stock.
• 4/24/2026 – Elevance Health had its price target raised by Barclays PLC from $393.00 to $408.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Elevance Health had its price target raised by The Goldman Sachs Group, Inc. from $350.00 to $370.00. They now have a “neutral” rating on the stock.
• 4/24/2026 – Elevance Health had its price target raised by Sanford C. Bernstein from $384.00 to $424.00. They now have an “outperform” rating on the stock.
• 4/23/2026 – Elevance Health was given a new $364.00 price target by Leerink Partners.
• 4/23/2026 – Elevance Health had its price target raised by Deutsche Bank Aktiengesellschaft from $332.00 to $363.00. They now have a “hold” rating on the stock.
• 4/23/2026 – Elevance Health had its price target raised by Evercore Inc from $345.00 to $360.00.
• 4/23/2026 – Elevance Health had its price target raised by Robert W. Baird from $317.00 to $331.00. They now have a “neutral” rating on the stock.
• 4/20/2026 – Elevance Health had its price target lowered by Jefferies Financial Group Inc. from $395.00 to $391.00. They now have a “buy” rating on the stock.
• 4/15/2026 – Elevance Health had its price target lowered by Robert W. Baird from $340.00 to $317.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Elevance Health had its price target lowered by Truist Financial Corporation from $390.00 to $375.00. They now have a “buy” rating on the stock.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s payout ratio is 29.26%.

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.